共 88 条
[1]
Paik PK(2020)Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations N Engl J Med 383 931-943
[2]
Felip E(2020)Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer N Engl J Med 383 944-957
[3]
Veillon R(2021)Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study Lancet Respir Med 9 1154-1164
[4]
Wolf J(2021)Savolitinib: first approval Drugs 81 1665-1670
[5]
Seto T(2020)Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 29iv 192-237
[6]
Han JY(2022)MET-targeted therapies and clinical outcomes: a systematic literature review Mol Diagn Ther 26 203-227
[7]
Lu S(2012)Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research Value Health 15 940-947
[8]
Fang J(2018)Methods for population-adjusted indirect comparisons in health technology appraisal Med Decis Mak 38 200-211
[9]
Li X(2021)Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/−bevacizumab for the first-line treatment of non-squamous NSCLC: a matching-adjusted indirect comparison Lung Cancer 155 175-182
[10]
Markham A(2020)Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer J Comp Eff Res 9 861-876